CAR T-Cell Therapy Results Reported in The New England Journal of Medicine

This week it is exciting to see the results of CAR T-cell therapy reported fully in The New England Journal of Medicine (NEJM). Results using the bb2121 anti-BCMA CAR T-cells were reported previously in abstract form at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. But the NEJM article provides important details about safety (the primary endpoint for this phase I study), as well as the anti-myeloma activity of the CAR T-cells directed against the BCMA (B-cell maturation antigen) on the myeloma cells of the relapsed/refractory-treated patients.

Of mice and men: research gone awry

A Boston data scientist’s new Twitter account calls out media for touting early research results. A headline like “Scientists Uncover a Protein That Seems to Fight Aging in Our Skin” is legit, for example, if by “our” you mean “mice.” IMF Chairman Brian G.M. Durie, MD has always warned: “Be cautious about early laboratory results. No matter how exciting, they just might not apply in the clinic.”

A Celebration of Science & Knowledge

At the recent VUB Honorary Doctorate Awards Ceremony at the University of Brussels, the focus was on “Figures That Matter.” The word “figures” had a double meaning: numbers and facts, as well as individuals and personalities. Susie and I received the award for scientific research and education in the field of myeloma. The fundamental meaning of the university’s theme for the awards was that knowledge is indeed powerful. It must be sought and communicated. And using knowledge—at all costs—really matters.

In the News: New Drug Updates and Notes on the Environment

IV infusionReports from the frontlines of myeloma drug development have been in the news lately. Here is a look at the latest developments: